Motor complications in Parkinson's disease: Ten year follow‐up study

Parkinson's disease (PD) can be symptomatically controlled with standard treatments; however, after a few years, this response typically declines and most patients develop motor complications. We carried out a prospective practice‐based study to evaluate the evolution appearance and evolution of motor complications in 64 de novo PD patients over 5 years and in 38 PD patients over 10 years. We studied untreated patients from initial assessment at basal conditions and evaluated every 6 months thereafter with treatment (levodopa versus other drugs). The follow‐up assessments were performed with the Unified Parkinson's Disease Rating Scale (UPDRS). At each assessment, patients were monitored regarding the development of dyskinesias, motor fluctuations, freezing, loss of postural reflexes, and cognitive impairment. We observed a significant improvement in UPDRS scores during the first year, then a progressive decline, more evident after the third year. Motor complications increased after the third year, and at the end of the survey (tenth year); drug‐induced dyskinesias and motor fluctuations were experienced (71.1 and 94.7%, respectively). After the first decade, many complications arose from the non‐levodopa–responsive features of the disease (cognitive impairment was present in 52.6% and gait freezing in 71.1%). Initial medication may influence medium‐term complications but not long‐term problems. Most long‐term disabling problems of PD were related to non‐levodopa‐responsive features. © 2010 Movement Disorder Society.

[1]  A. Schapira Future directions in the treatment of Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[2]  H. Reichmann,et al.  Non-motor dysfunction in Parkinson's disease. , 2007, Parkinsonism & related disorders.

[3]  John Seibyl,et al.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. , 2000, JAMA.

[4]  Werner Poewe,et al.  Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa , 2007, Movement disorders : official journal of the Movement Disorder Society.

[5]  M. Steiger Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease , 2007, European journal of neurology.

[6]  M. Hely,et al.  Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years , 2005, Movement disorders : official journal of the Movement Disorder Society.

[7]  K. Beusterien,et al.  Antipsychotic drug use among nursing home residents taking rivastigmine. , 2006, Journal of the American Medical Directors Association.

[8]  M. Hely,et al.  The Sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years , 1999, Journal of neurology, neurosurgery, and psychiatry.

[9]  Mick Jagger,et al.  (I Can't Get No) Satisfaction , 2011 .

[10]  A. Lees,et al.  Ten-year follow-up of three different initial treatments in de-novo PD: A randomized trial , 2001 .

[11]  M. Muenter,et al.  Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.

[12]  D. Brooks,et al.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.

[13]  A. Siderowf,et al.  Test–Retest reliability of the Unified Parkinson's Disease Rating Scale in patients with early Parkinson's disease: Results from a multicenter clinical trial , 2002, Movement disorders : official journal of the Movement Disorder Society.

[14]  A. Lang,et al.  Levodopa‐related motor complications—Phenomenology , 2008, Movement disorders : official journal of the Movement Disorder Society.

[15]  O Rascol A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group , 2000 .

[16]  A. Barbeau L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. , 1969, Canadian Medical Association journal.

[17]  C. Tanner,et al.  Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.

[18]  Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. , 2002, JAMA.

[19]  Fabrizio Stocchi,et al.  Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications , 2006, The Lancet Neurology.

[20]  John Seibyl,et al.  Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. , 2004, Archives of neurology.

[21]  V. Fung,et al.  Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone , 2009, Movement disorders : official journal of the Movement Disorder Society.

[22]  A. Lees,et al.  Ten-year follow-up of three different initial treatments in de-novo PD , 2001, Neurology.

[23]  E. Meseguer,et al.  Motor Complications in Parkinson Disease:: A Prospective Follow-Up Study , 2004, Clinical neuropharmacology.